Endoparasitic 2

Miziziziz · 2024 · $11.99 · Action · deal grade B

Measured on 2026-10-05 14:40 UTC. The whole catalog is re-measured daily; a game that just launched can move fast between passes.

Estimated net residual revenue: $533 to $800 per month
Opportunity: $866 per month at x1.30 dormancy
Estimated lifetime owners: 25.4k
87% positive across 669 reviews · 7.6 reviews/month

Why it's flagged

Developer active, last post 9 months ago
Studio active elsewhere (6 titles tracked), so this one may welcome a partner
Store page localized in only 1 language(s)
Last discounted 0 months ago, 5 sales in the last 12 months

Analyst notes (AI-assisted)

Note written 2026-09-05; the live figures above take precedence over any numbers in it.

Endoparasitic 2 is a 2024 survival-horror action title from Deep Root Interactive that refines its predecessor with resource management, exploration, and dynamic encounter avoidance.

This is a quiet indie success with solid community approval (87% positive) and consistent low-key residuals, but it operates in a saturated genre without licensed IP or network effects to anchor growth. The title is a self-published sequel from an operating studio with modest reach; it makes a case for patient catalog hold rather than urgent intervention. Interest here depends on whether a buyer sees dormant regional upside (Russian and Chinese review clusters suggest underexploited markets) or simply wants to preserve a well-reviewed backlist asset. Most realistic play: watch.

Risk: Survival-horror action is crowded; without franchise momentum or marketing spend, discoverability remains constrained despite positive sentiment.
Risk: Developer communication has been quiet for nearly 8 months; no updates, patches, or DLC roadmap are visible.
Risk: Current player base is minimal, with no promotional activity in the past 12 months and zero impulse-friendly discount patterns to drive trial.

This case as Markdown · Estimates carry ±30-50% error per title.